Evidence-based clinical review Blood-Based Colorectal Cancer Screening in Family Practice: Where Shield Fits Among FIT, Stool DNA, and Colonoscopy A practical framework for average-risk adults who remain unscreened or decline preferred modalities Abstract Background: The U.S. Food
Gastroenterology
C. difficile in 2026: Are We Finally Preventing Recurrence More Effectively?
Resistant Starch, Visceral Fat, and the 40 g/day Research Benchmark: A New GlobalRPh Calculator
GlobalRPh Clinical Nutrition Tool Resistant Starch, Visceral Fat, and the 40 g/day Research Benchmark: A New GlobalRPh Calculator An evidence-based review of resistant starch intake, the 40 g/day RS2 exposure used in key human trials, visceral adipose physiology, and a practical calculator for estimating daily intake. Open
Insulin Resistance in Non-Obese Patients: The “Metabolically Obese Normal Weight” Paradox
Insulin Resistance in Non-Obese Patients: The "Metabolically Obese Normal Weight” Paradox Review Abstract Normal body mass index (BMI) has long been used as a convenient and widely accepted screening tool for assessing overweight, obesity, and cardiometabolic risk. Although BMI remains valuable for population level surveillance and initial clinical
Obesity, Metabolic Syndrome, and ‘Difficult-to-Treat’ Psoriatic Arthritis: Is Inflammation Only Half the Story?
Obesity, Metabolic Syndrome, and ‘Difficult-to-Treat’ Psoriatic Arthritis Is Inflammation Only Half the Story Review Abstract Psoriatic arthritis (PsA) is a chronic, immune mediated inflammatory musculoskeletal disease that affects a substantial proportion of individuals with psoriasis. Characterized by peripheral arthritis, enthesitis, dactylitis, axial involvement, and progressive joint damage, PsA is associated
Ozempic Nation: Paradigm Shift or Public Health Mirage?
Ozempic Nation Paradigm Shift or Public Health Mirage Review Abstract The emergence of glucagon-like peptide-1 (GLP-1) receptor agonists and related incretin-based therapies has transformed the management of obesity and type 2 diabetes mellitus. Semaglutide, marketed as Ozempic for diabetes and Wegovy for obesity, initiated a major shift in
IBS Next-Generation Therapies: Low FODMAP Diets, Neuromodulators, Digital Cognitive Behavioral Therapy, and Microbiome-Based Interventions
IBS Next-Generation Therapies: Low FODMAP Diets, Neuromodulators, Digital Cognitive Behavioral Therapy, and Microbiome-Based Interventions Review Abstract Background Irritable bowel syndrome (IBS) is a chronic disorder of gut–brain interaction characterized by abdominal pain associated with altered bowel habits. Conventional therapies often provide incomplete symptom relief, leading to
Post-Polypectomy Surveillance: Are We Over-Scoping Patients (and Under-Scoping the High-Risk Ones)?
Post-Polypectomy Surveillance: Are We Over-Scoping Patients (and Under-Scoping the High-Risk Ones)? Review Key Takeaways Post polypectomy surveillance is a critical component of colorectal cancer prevention strategies, aimed at reducing the incidence of interval colorectal cancers through timely follow up colonoscopy after adenoma removal. However, current surveillance practices
Microbiome Therapeutics After Recurrent C. diff: What’s Real, What’s Hype, and What’s Next?
Microbiome Therapeutics After Recurrent C. diff What’s Real, What’s Hype, and What’s Next Review Abstract Recurrent Clostridioides difficile infection (rCDI) remains a significant and persistent challenge in clinical practice, occurring in approximately 20 to 30 percent of patients after an initial episode. The risk of recurrence increases with
AI in the Endoscopy Suite: Adenoma Detection Booster or Expensive Distraction?
AI in the Endoscopy Suite Adenoma Detection Booster or Expensive Distraction Review Abstract Artificial intelligence systems designed for adenoma detection during colonoscopy represent a remarkable advancement in gastrointestinal endoscopy and colorectal cancer prevention. Colonoscopy remains the gold standard for colorectal cancer screening, yet its effectiveness is highly operator
